Terms: = Breast cancer AND CD52, CDW52, EDDM5 AND Prognosis
4 results:
1. cd52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic and immune implications of a novel 7-methylguanosine-related microRNA signature in breast invasive carcinoma: from exploration to validation.
Li AY; Xiao HN; Zhao ZY; Xiang C; Chen ZY; Wang PX; Xia Y; Yu B; Li H; Xiao T
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9105-9128. PubMed ID: 37171615
[TBL] [Abstract] [Full Text] [Related]
3. [CD40LG is a novel immune- and stroma-related prognostic biomarker in the tumor microenvironment of invasive breast cancer].
Guo L; Ma Y; Li T; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Sep; 42(9):1267-1278. PubMed ID: 36210698
[TBL] [Abstract] [Full Text] [Related]
4. CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive breast Carcinoma That Modulates the Tumor Microenvironment.
Chen Y; Meng Z; Zhang L; Liu F
Front Immunol; 2021; 12():664845. PubMed ID: 33968066
[TBL] [Abstract] [Full Text] [Related]
